Neelima Denduluri, MD @ndenduluri1 of Virginia Cancer Specialists @VCSpecialists discusses CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction.
Read here:Â https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e13029